JW Pharmaceutical Corporation (001065.KS)
KRW 29450.0
(-1.01%)
KRW 29450.0
(-1.01%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 89.22 Billion KRW | 44.43% |
| 2022 | 73.45 Billion KRW | 74.19% |
| 2021 | 45.12 Billion KRW | 211.46% |
| 2020 | 15.07 Billion KRW | 712.32% |
| 2019 | -2.86 Billion KRW | -106.4% |
| 2018 | 39.33 Billion KRW | 45.24% |
| 2017 | 27.28 Billion KRW | -22.13% |
| 2016 | 38.9 Billion KRW | 7.08% |
| 2015 | 36.77 Billion KRW | -6.58% |
| 2014 | 34.68 Billion KRW | -16.0% |
| 2013 | 39.64 Billion KRW | 64.64% |
| 2012 | 23.05 Billion KRW | -11.17% |
| 2011 | 26.06 Billion KRW | -10.49% |
| 2010 | 35.21 Billion KRW | -27.13% |
| 2009 | 39.83 Billion KRW | 16.24% |
| 2008 | 40.79 Billion KRW | -10.39% |
| 2007 | 41.06 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 31.12 Billion KRW | 1.89% |
| 2024 Q2 | 16.37 Billion KRW | -46.88% |
| 2023 Q3 | 81.97 Billion KRW | -1.94% |
| 2023 Q2 | 83.59 Billion KRW | 10.35% |
| 2023 Q1 | 75.75 Billion KRW | 143.92% |
| 2023 FY | - KRW | 44.43% |
| 2023 Q4 | 38 Billion KRW | -53.63% |
| 2022 Q4 | 31.05 Billion KRW | 62.48% |
| 2022 FY | - KRW | 74.19% |
| 2022 Q1 | 17.7 Billion KRW | 2.81% |
| 2022 Q2 | 14.66 Billion KRW | -17.18% |
| 2022 Q3 | 19.11 Billion KRW | 30.36% |
| 2021 Q1 | 12.18 Billion KRW | 103.06% |
| 2021 Q2 | 5.45 Billion KRW | -55.24% |
| 2021 Q3 | 12.52 Billion KRW | 129.7% |
| 2021 FY | - KRW | 211.46% |
| 2021 Q4 | 17.21 Billion KRW | 37.47% |
| 2020 Q4 | 5.99 Billion KRW | 34.73% |
| 2020 Q1 | 4.74 Billion KRW | 120.4% |
| 2020 FY | - KRW | 712.32% |
| 2020 Q3 | 4.45 Billion KRW | 39494.78% |
| 2020 Q2 | 11.24 Million KRW | -99.76% |
| 2019 Q1 | 5.29 Billion KRW | 319.08% |
| 2019 FY | - KRW | -106.4% |
| 2019 Q2 | 6.83 Billion KRW | 29.08% |
| 2019 Q4 | -23.28 Billion KRW | -375.23% |
| 2019 Q3 | 8.45 Billion KRW | 23.8% |
| 2018 Q4 | -2.41 Billion KRW | -118.17% |
| 2018 Q3 | 13.3 Billion KRW | -17.08% |
| 2018 Q2 | 16.04 Billion KRW | 34.67% |
| 2018 Q1 | 11.91 Billion KRW | 1171.38% |
| 2018 FY | - KRW | 45.24% |
| 2017 Q4 | -1.11 Billion KRW | -111.36% |
| 2017 Q3 | 9.78 Billion KRW | 65.78% |
| 2017 Q2 | 5.9 Billion KRW | -20.35% |
| 2017 Q1 | 7.41 Billion KRW | -51.78% |
| 2017 FY | - KRW | -22.13% |
| 2016 Q3 | 2.05 Billion KRW | -68.39% |
| 2016 Q2 | 6.5 Billion KRW | -37.51% |
| 2016 Q1 | 10.4 Billion KRW | 10.63% |
| 2016 FY | - KRW | 7.08% |
| 2016 Q4 | 15.37 Billion KRW | 648.07% |
| 2015 Q1 | 8.49 Billion KRW | -37.53% |
| 2015 Q4 | 9.4 Billion KRW | 31.3% |
| 2015 Q3 | 7.16 Billion KRW | 2.3% |
| 2015 Q2 | 7 Billion KRW | -17.56% |
| 2015 FY | - KRW | -6.58% |
| 2014 FY | - KRW | -16.0% |
| 2014 Q4 | 13.59 Billion KRW | 65.72% |
| 2014 Q3 | 8.2 Billion KRW | 337.15% |
| 2014 Q2 | 1.87 Billion KRW | -82.37% |
| 2014 Q1 | 10.64 Billion KRW | 7.51% |
| 2013 Q4 | 9.9 Billion KRW | -0.84% |
| 2013 FY | - KRW | 64.64% |
| 2013 Q1 | 9.84 Billion KRW | 29.54% |
| 2013 Q2 | 11.13 Billion KRW | 13.02% |
| 2013 Q3 | 9.98 Billion KRW | -10.29% |
| 2012 Q4 | 7.6 Billion KRW | 9.79% |
| 2012 FY | - KRW | -11.17% |
| 2012 Q3 | 6.92 Billion KRW | 451.45% |
| 2012 Q1 | 10.22 Billion KRW | 0.0% |
| 2012 Q2 | -1.97 Billion KRW | -119.27% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 10.75 Billion KRW | 10.64% |
| 2011 Q1 | 9.72 Billion KRW | 75.9% |
| 2011 Q3 | 5.09 Billion KRW | -52.66% |
| 2011 FY | - KRW | -10.49% |
| 2010 Q4 | 5.52 Billion KRW | 36.99% |
| 2010 FY | - KRW | -27.13% |
| 2010 Q1 | 13.91 Billion KRW | 10.82% |
| 2010 Q3 | 4.03 Billion KRW | -47.86% |
| 2010 Q2 | 7.73 Billion KRW | -44.38% |
| 2009 Q2 | 13.11 Billion KRW | 16.72% |
| 2009 Q4 | 12.55 Billion KRW | 111.49% |
| 2009 Q3 | 5.93 Billion KRW | -54.72% |
| 2009 Q1 | 11.23 Billion KRW | 205.8% |
| 2009 FY | - KRW | 16.24% |
| 2008 Q2 | 14.6 Billion KRW | 14.8% |
| 2008 Q3 | 5.85 Billion KRW | -59.89% |
| 2008 FY | - KRW | -10.39% |
| 2008 Q4 | 3.67 Billion KRW | -37.28% |
| 2008 Q1 | 12.71 Billion KRW | 369.21% |
| 2007 Q4 | 2.71 Billion KRW | -70.43% |
| 2007 Q1 | 14.09 Billion KRW | 0.0% |
| 2007 Q2 | 15.14 Billion KRW | 7.41% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q3 | 9.16 Billion KRW | -39.46% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -1736.445% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 36.886% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 239.329% |
| HANDOK Inc. | 35.06 Billion KRW | -154.431% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 8707.256% |
| Yuhan Corporation | 127.43 Billion KRW | 29.986% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | -137.788% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 511.391% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 72.406% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -1687.874% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -490.152% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -2508.048% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -1871.117% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -151.422% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -1736.445% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 583.01% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -1261.116% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 281.005% |
| JW Holdings Corporation | 187.88 Billion KRW | 52.513% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 274.162% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 68.543% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 340.702% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -575.423% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -654.326% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -378.271% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -1736.445% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | -62.299% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 45.898% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 0.0% |
| Yuhan Corporation | 127.43 Billion KRW | 29.986% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -166.522% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -1066.309% |
| Suheung Co., Ltd. | 77.02 Billion KRW | -15.828% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 0.0% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -143.543% |
| Korea United Pharm Inc. | 70.78 Billion KRW | -26.053% |
| CKD Bio Corp. | -1.63 Billion KRW | 5572.172% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | -79.183% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -174.007% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | -142.379% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 340.702% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | -43.247% |
| Boryung Corporation | 114.28 Billion KRW | 21.934% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 391.873% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -490.152% |
| JW Lifescience Corporation | 50.82 Billion KRW | -75.53% |